Leerink Swann Reiterates Buy Rating for Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by equities research analysts at Leerink Swann in a research note issued to investors on Monday.
Several other research firms have also recently commented on ALNY. Needham & Company LLC reissued a “buy” rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, August 5th. Cowen and Company reissued a “buy” rating and set a $150.00 target price on shares of Alnylam Pharmaceuticals in a research report on Sunday, August 7th. Goldman Sachs Group Inc. reissued a “neutral” rating and set a $65.00 target price (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 10th. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on Tuesday, August 9th. Finally, FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 8th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $113.62.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 78.09 on Monday. Alnylam Pharmaceuticals has a 1-year low of $49.96 and a 1-year high of $110.75. The firm’s market capitalization is $6.69 billion. The firm has a 50-day moving average price of $73.60 and a 200-day moving average price of $66.10.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter last year, the firm earned ($0.85) EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals will post ($4.65) earnings per share for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. raised its position in Alnylam Pharmaceuticals by 2,138.1% in the second quarter. Macquarie Group Ltd. now owns 20,143 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 19,243 shares during the period. Royal Bank of Canada raised its position in shares of Alnylam Pharmaceuticals by 63.0% in the second quarter. Royal Bank of Canada now owns 51,314 shares of the biopharmaceutical company’s stock valued at $2,847,000 after buying an additional 19,827 shares during the period. Public Employees Retirement System of Ohio raised its position in shares of Alnylam Pharmaceuticals by 3.6% in the second quarter. Public Employees Retirement System of Ohio now owns 28,961 shares of the biopharmaceutical company’s stock valued at $1,607,000 after buying an additional 1,000 shares during the period. Calvert Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 36 shares during the period. Finally, Amalgamated Bank bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $859,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.